Gelonghui, May 22丨Sinopharm Hyundai (600420.SH) announced that on June 10, 2021, it signed a “Cooperation Framework Agreement on Commissioning Exclusive Production and Exclusive Sales of Pharmaceutical Products and Provision of Marketing Services” with Xi'an Xintong Pharmaceutical Research Co., Ltd. (hereinafter referred to as Xi'an Xintong), agreeing that Xi'an Xintong is in the R&D process, has intellectual property rights, and entrusts three pharmaceutical products as drug marketing license holders to Sinopharm Hyundai for exclusive production and exclusive sale.
In August 2022, due to policy influence, the two sides reached an agreement on CE-fosphenytoin injection, one of the cooperative products, after negotiations, agreed to terminate the agreement on this product in the cooperation framework agreement, and signed the “CE-fosphenytoin Sodium Injection Product Service Termination Agreement”. For details, please refer to the “Notice on the Progress of the Cooperation Framework Agreement” disclosed by the company on August 2, 2022. Up to now, the two sides have not carried out substantial cooperation on other products in the cooperation framework agreement.
<合作框架协议>Recently, the company received the “Notice of Termination” from Xi'an Xintong. Since the validity period of the original agreement will expire on June 10, 2024, it will be terminated at the end of the period, and will not be extended. After comprehensive evaluation and judgment, the company agreed not to extend the cooperation framework agreement after the expiration of the period.